Literature DB >> 11748002

The 5-aminolevulinic acid-induced porphyrin biosynthesis in benign and malignant cells of the skin.

K Lang1, K Bolsen, W Stahl, T Ruzicka, H Sies, P Lehmann, C Fritsch.   

Abstract

In fluorescence diagnosis and photodynamic therapy of neoplastic tissues 5-aminolevulinic acid is used to synthesize endogenous porphyrins as photosensitizers. The efficacy of neoplastic tissues to fluorescence diagnosis and photodynamic therapy is thought to be dependent on the total level of intralesional formed porphyrins. The available profiles of porphyrin metabolites in normal and in neoplastic cell lines after administration of 5-aminolevulinic acid vary considerably. Thus, this is the first in-vitro study which compares the porphyrin biosynthesis in normal skin cells (HaCaT, fibroblasts) with melanoma cells (Bro, SKMel-23, SKMel-28). After incubation with 1 mM 5-aminolevulinic acid, kinetics of porphyrin levels and metabolites were determined in the cells and the corresponding supernatants. Exogenous 5-aminolevulinic acid induced porphyrin formation in all cells with maximum values after an incubation period of 16-36 h. Increase of porphyrin levels varied from 10- to 80-fold (SKMel-28>HaCaT>fibroblasts>SKMel-23>>Bro) with minimum 1.5 times higher levels of porphyrins in the supernatants than in the cells. In cells and supernatants protoporphyrin and coproporphyrin were the predominantly formed porphyrin metabolites. Metastatic melanoma cells (SKMel-23, SKMel-28) accumulated much higher porphyrin levels than primary melanoma cells (Bro). In conclusion, by optimizing the treatment modalities, especially the light source, topical photodynamic therapy (PDT) could become a treatment alternative of melanoma metastases in progressive disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11748002     DOI: 10.1016/s1011-1344(01)00242-1

Source DB:  PubMed          Journal:  J Photochem Photobiol B        ISSN: 1011-1344            Impact factor:   6.252


  6 in total

1.  Correction of the biochemical defect in porphobilinogen deaminase deficient cells by non-viral gene delivery.

Authors:  Annika Johansson; Christer Möller; Pauline Harper
Journal:  Mol Cell Biochem       Date:  2003-08       Impact factor: 3.396

2.  In vitro evaluation of 5-aminolevulinic acid (ALA) loaded PLGA nanoparticles.

Authors:  Lei Shi; Xiuli Wang; Feng Zhao; Hansen Luan; Qingfeng Tu; Zheng Huang; Hao Wang; Hongwei Wang
Journal:  Int J Nanomedicine       Date:  2013-07-24

Review 3.  Susceptibility and Resistance Mechanisms During Photodynamic Therapy of Melanoma.

Authors:  Xin-Ying Li; Liu-Chang Tan; Li-Wen Dong; Wan-Qi Zhang; Xiao-Xiao Shen; Xiao Lu; Hong Zheng; Yuan-Gang Lu
Journal:  Front Oncol       Date:  2020-05-12       Impact factor: 6.244

4.  Improving in vitro photodynamic therapy through the development of a novel iron chelating aminolaevulinic acid prodrug.

Authors:  Alison Curnow; Alexis Perry; Mark Wood
Journal:  Photodiagnosis Photodyn Ther       Date:  2018-12-13       Impact factor: 3.631

5.  Improvement of DC vaccine with ALA-PDT induced immunogenic apoptotic cells for skin squamous cell carcinoma.

Authors:  Jie Ji; Zhixia Fan; Feifan Zhou; Xiaojie Wang; Lei Shi; Haiyan Zhang; Peiru Wang; Degang Yang; Linglin Zhang; Wei R Chen; Xiuli Wang
Journal:  Oncotarget       Date:  2015-07-10

6.  An experimental investigation of a novel iron chelating protoporphyrin IX prodrug for the enhancement of photodynamic therapy.

Authors:  Lizette Anayo; Anette Magnussen; Alexis Perry; Mark Wood; Alison Curnow
Journal:  Lasers Surg Med       Date:  2018-03-31       Impact factor: 4.025

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.